[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543188":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":32,"centralContacts":36,"locations":45,"responsibleParty":81,"collaborators":83,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":89,"sex":95,"minAge":96,"maxAge":11,"enrollmentInfo":97,"targetDuration":11,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":48,"whyStopped":11,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"The George Institute","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Conservative SBP Control","EXPERIMENTAL",null,[13],"Other: Conservative SBP Control",{"label":15,"type":10,"description":11,"interventionNames":16},"Moderate SBP Control",[17],"Other: Moderate SBP Control",{"label":19,"type":10,"description":11,"interventionNames":20},"Intensive SBP Control",[21],"Other: Intensive SBP Control",[23,26,29],{"type":6,"name":9,"description":24,"armGroupLabels":25,"otherNames":11},"No or minimal treatment; if there is a need to treat a patient with a very-high (\\>180 mmHg) baseline SBP, then the SBP reduction is 5-10mmHg or a target is 175-180 mmHg",[9],{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":11},"If the patient has a very high (\\>180 mmHg) or moderate high (160-180 mmHg) baseline SBP, SBP reduction is 10-20mmHg or a target of160±5 mmHg, which is higher; patients with low-high (150-160 mmHg) baseline SBP will not be treated",[15],{"type":6,"name":19,"description":30,"armGroupLabels":31,"otherNames":11},"SBP reduction by 30-50mmHg or a target of 140±5 mmHg, which is higher",[19],[33],{"name":34,"affiliation":5,"role":35},"Craig Anderson, PhD","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Xiaoying Chen, PhD","CONTACT","+61 2 8052 4549","xchen@georgeinstitute.org.au",{"name":34,"role":39,"phone":43,"phoneExt":11,"email":44},"+61 2 8052 4521","canderson@georgeinstitute.org.au",[46,64],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"The George Institute for Global Health","RECRUITING","Sydney","New South Wales","2000","Australia","AU",{"type":55,"coordinates":56},"Point",[57,58],151.20732,-33.86785,{"lat":58,"lon":57},[61,62],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},{"name":63,"role":39,"phone":43,"phoneExt":11,"email":44},"Craig Anderson, MD, PhD",{"facility":65,"status":48,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"University of Calgary","Calgary","Alberta","T2N 1N4","Canada","CA",{"type":55,"coordinates":72},[73,74],-114.08529,51.05011,{"lat":74,"lon":73},[77,79],{"name":78,"role":39,"phone":11,"phoneExt":11,"email":11},"Carol C Kenney, RN",{"name":80,"role":39,"phone":11,"phoneExt":11,"email":11},"Michael D Hill, MD",{"type":82,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[84,85],{"name":65,"class":6},{"name":86,"class":6},"Changhai Hospital","100543188","third-enhanced-control-of-hypertension-and-thrombectomy-stroke-domain-within-act-global-adaptive-platform-trial-100543188",false,"NCT06352619","Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial","Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL_ENCHANTED3\u002FMT)","ENCHANTED3\u002FMT","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Use of endovascular therapy (EVT) within 24 hours of symptom onset or last known well according to local guidelines;\n3. Sustained high systolic blood pressure ≥150 mmHg (2 readings \\\u003C10 mins apart) within 3 hours after completion of EVT.\n\nExclusion Criteria:\n\n1.Any definite contraindications to BP lowering treatment.","ALL","18 Years",{"count":98,"type":99},2000,"ESTIMATED","INTERVENTIONAL",[102],"NA","Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP \\\u003C130 mmHg), the others neutral effects in the SBP range 140-160 mmHg. The ENCHANTED3\u002FMT domain of the ACT-GLOBAL platform trial aims to test different approaches to the treatment of elevated SBP in post-EVT AIS patients to find an optimal BP management strategy. ENCHANTED3\u002FMT will randomize (1:1:1) up to 2,000 patients with SBP ≥150 mmHg post-EVT to conservative (no or minimal SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP \\[≥180mmHg\\]), moderate (SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP \\[150-160mmHg\\]), or intensive (SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher) BP management.",[105],"Ischemic Stroke, Acute",[107,108,109],"Blood Pressure","Endovascular Therapy","Ischemic Stroke","2024-11-18",{"date":112,"type":113},"2024-11-21","ACTUAL",{"date":115,"type":113},"2024-10-11",{"date":117,"type":99},"2026-05",{"name":5,"class":6},2]